Sökning: onr:"swepub:oai:DiVA.org:uu-457826" >
Delaying the inevit...
-
Burman, Joachim,1974-Uppsala universitet,Landtblom: Neurovetenskap
(författare)
Delaying the inevitable : Are disease modifying drugs for progressive MS worthwhile?
- Artikel/kapitelEngelska2021
Förlag, utgivningsår, omfång ...
-
Elsevier,2021
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-457826
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-457826URI
-
https://doi.org/10.1016/j.msard.2021.103134DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:vet swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Ocrelizumab and siponimod have a scientifically proven effect in progressive MS and decrease the risk of disability in the short-term. The primary endpoints in the pivotal trials of ocrelizumab and siponimod were reported as a hazard ratio of 3-month confirmed disability progression, which was reported to be 0.76-0.79. Based on this, both drugs were subsequently licensed for use in patients with progressive multiple sclerosis. Hazard ratios are not easily communicated to patients and therefore the alternative endpoint average postponement of disability was calculated with data from the pivotal trials. After two years of treatment, the average postponement of disability was 16 days per year with ocrelizumab and 19 days with siponimod. Over time, the average postponement of disability reached a plateau, when further treatment added little value. Taken together, these data suggest that these interventions have a short-lived and limited clinical effect in patients with progressive MS.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Uppsala universitetLandtblom: Neurovetenskap
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Multiple Sclerosis and Related Disorders: Elsevier542211-03482211-0356
Internetlänk
Hitta via bibliotek
Till lärosätets databas